|
||||||||||||||||
HUM-MOLGEN -> Events -> Meetings and Conferences | ||||||||||||||||
GENOME JAPAN | ||||||||||||||||
December 06, 2000 | ||||||||||||||||
Cambridge Healthtech Institute, Tokyo, Japan March 26-28, 2001 If there was any questions previously, the publication of the draft sequence for the human genome has made it very clear that genomics is going to play an increasingly critical role in the development of pharmaceuticals in the years to come. Such specialties as bioinformatics, gene expression monitoring, functional genomics, proteomics and pharmacogenomics will all need to be melded into efficient strategies to accelerate drug discovery and development. These tools are being brought to bear on the key applied tasks of target identification and validation, as well as clinical evaluation of compounds being developed. This conference brings together some of the leading examples of researchers from around the world who will discuss their experience and insight into these technologies, and the impact that new approaches can have on drug development. |
||||||||||||||||
Organized by: | Cambridge Healthtech Institute | |||||||||||||||
Invited Speakers: | Dr. Charlie Rodi, Sequenom, Inc. Dr. Trevor Nicholls, Oxagen, Ltd. Dr. Jan Michel, LION Bioscience AG Dr. Andreas Duesterhoeft, QIAGEN Genomics, Inc. Dr. Jacquelyn Fetrow, GeneFormatics, Inc. |
|||||||||||||||
Deadline for Abstracts: | March 2, 2001 | |||||||||||||||
Registration: | Available on-line | |||||||||||||||
E-mail: | jlaakso@healthtech.com | |||||||||||||||
Posted by: | Jennifer Laakso | |||||||||||||||
Host: | wks217.healthtech.com | |||||||||||||||
|
||||||||||||||||
Generated by meetings and positions 5.0 by Kai Garlipp |